BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38058823)

  • 21. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
    Wang Y; Chen H; Jiao X; Wu L; Yang Y; Zhang J; Wu L; Liu C; Zhuo N; Li S; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Lu Z; Zhang H; Shen L
    Cancer Immunol Immunother; 2022 Jan; 71(1):111-120. PubMed ID: 34028566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.
    Yan HHN; Lai JCW; Ho SL; Leung WK; Law WL; Lee JFY; Chan AKW; Tsui WY; Chan ASY; Lee BCH; Yue SSK; Man AHY; Clevers H; Yuen ST; Leung SY
    Gut; 2017 Sep; 66(9):1645-1656. PubMed ID: 27329244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
    Fennell LJ; Clendenning M; McKeone DM; Jamieson SH; Balachandran S; Borowsky J; Liu J; Kawamata F; Bond CE; Rosty C; Burge ME; Buchanan DD; Leggett BA; Whitehall VLJ
    Fam Cancer; 2018 Jan; 17(1):63-69. PubMed ID: 28573495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
    Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
    Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer.
    Feng F; Sun H; Zhao Z; Sun C; Zhao Y; Lin H; Yang J; Xiao Y; Wang W; Wu D
    J Oncol; 2022; 2022():6567998. PubMed ID: 35874638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis.
    Tu J; Park S; Yu W; Zhang S; Wu L; Carmon K; Liu QJ
    Sci Rep; 2019 Dec; 9(1):18557. PubMed ID: 31811196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in DNA damage repair gene mutations between left- and right-sided colorectal cancer.
    Huang W; Li W; Xu N; Li H; Zhang Z; Zhang X; He T; Yao J; Xu M; He Q; Guo L; Zhang S
    Cancer Med; 2023 May; 12(9):10187-10198. PubMed ID: 37096801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB.
    Miao XY; Wu H; Ye BC; Yi QW; Lin FN; Wang YL; Ren CL; Jiang YF; Li A
    Sci Rep; 2022 Dec; 12(1):20734. PubMed ID: 36456601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
    Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
    World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data.
    Jiang M; Jia Y; Han J; Shi J; Su C; Zhang R; Xing M; Jin S; Zong H
    Front Genet; 2022; 13():963964. PubMed ID: 36479248
    [No Abstract]   [Full Text] [Related]  

  • 36. Majority of
    Middha S; Yaeger R; Shia J; Stadler ZK; King S; Guercio S; Paroder V; Bates DDB; Rana S; Diaz LA; Saltz L; Segal N; Ladanyi M; Zehir A; Hechtman JF
    JCO Precis Oncol; 2019; 3():. PubMed ID: 31008436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.
    Jiang W; Cheng H; Yu L; Zhang J; Wang Y; Liang Y; Lou F; Wang H; Cao S
    Cancer Med; 2023 Mar; 12(6):6649-6658. PubMed ID: 36440695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer.
    Salem ME; Battaglin F; Goldberg RM; Puccini A; Shields AF; Arguello D; Korn WM; Marshall JL; Grothey A; Lenz HJ
    Oncologist; 2020 May; 25(5):404-413. PubMed ID: 31848314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.
    Bao X; Zhang H; Wu W; Cheng S; Dai X; Zhu X; Fu Q; Tong Z; Liu L; Zheng Y; Zhao P; Fang W; Liu F
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.